ライフサイエンスコーパス: antibody test

1 HCV RNA with the use of a more sensitive HCV-antibody test).

2 infection during the epidemic (positive IgM antibody tests).

3 t year, and 1861 did not provide samples for antibody testing).

4 gainst endomysium (P>.05 vs controls for all antibodies tested).

5 s demonstrate a success rate of 82% (100/122 antibodies tested).

6 RNA test done within 6 months of a positive antibody test.

7 aving an RNA test after a first positive HCV antibody test.

8 antibody tests outperformed a spike protein antibody test.

9 cted erythrocytes in an indirect fluorescent antibody test.

10 tibody (HCV AB) using the OraQuick HCV Rapid Antibody Test.

11 ssay to the gold standard direct fluorescent-antibody test.

12 50 had sera previously referred for selected antibody tests.

13 included gastrointestinal symptoms or serum antibody tests.

14 untary HIV counseling and testing by 2 rapid antibody tests.

15 or subsequent use in vaccine and therapeutic antibody testing.

16 sive and scalable alternative to blood-based antibody testing.

17 cterise the antigen and develop an assay for antibody testing.

18 diagnosis depends on sensitive and specific antibody testing.

19 to 47 months (mean = 26.1 months) before JCV antibody testing.

20 erum antitransglutaminase and antiendomysial antibody testing.

21 he newborn for rubella immunoglobulin (Ig) M antibody testing.

22 hHepc knock-in mice were produced to enable antibody testing.

23 anti-cyclic citrullinated peptide (anti-CCP) antibody testing.

24 al risk stratification, and state-of-the-art antibody testing.

25 c to B. burgdorferi, by indirect fluorescent antibody testing.

26 oximately 10% compared with conventional HIV antibody testing.

27 17,971 had samples available for SARS-CoV-2 antibody testing.

28 ned at colonoscopy and this was confirmed on antibody testing.

29 ripheral blood samples were obtained for HIV antibody testing.

30 HSV-2 and T. pallidum were detected by serum antibody testing.

31 The primary objective was safety, including antibody testing.

32 tein was not detected with either of the two antibodies tested.

33 concentration values for the three anti-CD4 antibodies tested.

34 n fact, it was not neutralized by any of the antibodies tested.

35 on geniculocortical axons for all five TrkB antibodies tested.

36 ars to play only a limited role in the three antibodies tested.

37 f the four different monoclonal anti-V3 loop antibodies tested.

38 id testing, mainly through nucleic acid- and antibody- testing.

39 With antibody testing, 0.2% of patients (2 of 1044) developed

40 th nonspecific bands of approximately 20% of antibodies tested (5/25).

41 Among 11 267 patients, proportions of HCV antibody tested (52.5% in 2013-2014 vs 73.3% in 2015-201

42 T-Def eight [11%] of 75; p<0.0001) and rapid antibody test (54 [53%] of 101 vs eight [11%] of 74; p<0

43 women who were positive by both IgA and IgM antibody tests, 61 (85.9%) were acutely infected, wherea

44 e directly compared central findings from 16 antibody tests (8 for TGA-IgA, 1 for TGA-IgG, 6 for IgG

45 osis of AHR compared with the donor-specific antibody test (90%).

46 9.3% and 99.7%) than using the spike protein antibody test (97.8%; P <= 0.002).

47 pecificity was higher using the nucleocapsid antibody tests (99.3% and 99.7%) than using the spike pr

48 Two nucleocapsid antibody tests (Abbott IgG and Roche total antibody) and

49 re calculated to estimate the performance of antibody tests against tissue transglutaminase (TG2), de

50 Therefore, we suggest that the HCV antibody testing algorithm for the VITROS assay might be

51 SARS-CoV-2 antibody testing allows quantitative determination of di

52 m) as well as 1 algorithm that relies on HIV antibody testing alone (Antibody algorithm).

53 atients with typical symptoms and a positive antibody test, although a detailed clinical and neurophy

54 The two antibodies tested and the expressed scFv all efficiently

55 n of Bax and p53 was found regardless of the antibodies tested and was specific since Bcl-xL/p53 comp

56 NA gene fragments by an indirect fluorescent antibody test and a nested PCR assay, respectively.

57 CV infection was assessed via a positive HCV antibody test and a positive HCV RNA test.

58 e positive for E. canis by immunofluorescent antibody test and in various phases of acute or chronic

59 urrently, there is an increase in demand for antibody testing and a large number of tests are already

60 Bordetella culture and/or direct fluorescent antibody testing and a second LightCycler PCR assay (tar

61 n of S. neurona exposure risk based on serum antibody testing and assessed risk factors for exposure

62 tial that the clinical phenotype guides both antibody testing and clinical management.

63 ldren to support diagnostic decisions, drive antibody testing and generate disease mechanism hypothes

64 undiagnosed HCV disease, as suggested by HCV antibody testing and HCV polymerase chain reaction and c

65 action (MLR), cell-mediated lysis (CML), and antibody testing and in vivo by kidney transplantation.

66 tive living organ donors, and to conduct HIV antibody testing and NAT as close to the time of donatio

67 r autoimmune encephalitis are too reliant on antibody testing and response to immunotherapy, which mi

68 ths), saliva was collected for anonymous HCV antibody testing and risk behavior data were obtained th

69 HCV is used to confirm a positive result on antibody testing and to provide prognostic information f

70 Clinicians should consider antibody testing and vaccination for this vulnerable pop

71 Indirect fluorescence antibody tests and enzyme-linked immunosorbent assays ma

72 IV) infection cannot be diagnosed by routine antibody tests and is rarely diagnosed in clinical pract

73 seroconversion rates of 86%-96% by other VZV antibody tests and suggest that many cases of varicella

74 justed risk ratio (aRR) for receiving an HCV antibody test, and costs were estimated using activity-b

75 -antibody combination, HIV-1 and HIV-2 rapid antibody test, and quantitative anti-gp120 IgG ELISA.

76 plement fixation test, the immunofluorescent antibody test, and Western blot analysis.

77 9 and risk factors, received a point-of-care antibody test, and, if agreed, donated a blood sample fo

78 ative to control was reduced at all doses of antibody tested, and the magnitude of growth inhibition

79 %) were positive for SARS-CoV-2 by RT-PCR or antibody testing, and 164 (88%) were hospitalized after

80 r DNA amplification test, direct fluorescent antibody testing, and a DNA amplification test to detect

81 aracteristics, OMG symptoms, results of AChR antibody testing, and progression time to generalized my

82 at ATG produces positive results in anti-HLA antibody testing, and treatment to remove ATG abolishes

83 itis A, 659 (12.4%) had negative hepatitis A antibody tests, and 1671 (31.4%) had no testing or vacci

84 titis A, 122 (7.5%) had negative hepatitis A antibody tests, and 535 (32.7%) had no testing or vaccin

85 results of heparin-induced platelet factor 4 antibody tests, and outcomes.

86 ing total IgA levels, IgG deamidated gliadin antibody tests, and TG2-IgG testing in that circumstance

87 Among several anti-FVIII antibodies tested (anti-C1 (GMA8011), anti-C2 (ESH4 and

88 Groups, the relationships of donor-specific antibody tests (anti-HLA and non-HLA) with transplant hi

89 A 2-tiered antibody testing approach is recommended, but single-tie

90 atients, but clinical features and anti-GQ1b antibody testing are diagnostically more informative.

91 ss the world, options for easy, non-invasive antibody testing are required.

92 syndrome coronavirus 2 (SARS-CoV-2)-specific antibody tests are increasingly being used to estimate t

93 y-determining regions (CDRs) from monoclonal antibodies tested as synthetic peptides display anti-inf

94 hese results support the use of saliva-based antibody testing as a noninvasive and scalable alternati

95 ure fail to receive the recommended anti-HCV antibody test at age >=18 months.

96 cardiolipin, and anti-beta(2)-glycoprotein I antibody tests at baseline had positive results at 24 we

97 We compared the results of single-antigen antibody testing, autoreactive and alloreactive flow cyt

98 Adding HIV and HCV viral RNA testing to antibody testing averts 14.8-30.3 HIV and 3.7-7.7 HCV in

99 As antibody testing becomes more widely available, and many

100 l three neutralizing, LF-specific monoclonal antibodies tested bound specific peptide sequences that

101 e synergy with all tumor-specific monoclonal antibodies tested by increasing phagocytosis in vitro an

102 y SARS-CoV-2 rRT-PCR and sera for SARS-CoV-2 antibodies testing by enzyme-linked immunosorbent assay

103 We tested the accuracy of the JCV serum antibody test by comparing the results of JCV serology t

104 IgA antibeta 2 Glycoprotein I (beta2GPI) antibodies test can identify some patients with antiphos

105 cent infection with T. gondii Toxoplasma IgA antibody testing can therefore improve the accuracy of a

106 HIV antibody tests cannot be used to reconfirm HIV diagnosis

107 sting the original specimens with a blocking antibody test (Chlamydiazyme), a cytospin DFA (MicroTrak

108 ack of standardized methods for anti-retinal antibody testing continues to challenge the interpretati

109 Multiplex P. falciparum antibody testing could provide estimates of long-term an

110 longitudinal changes in the results of BVDV antibody tests could offer a novel, complementary approa

111 etions were sent to central laboratories for antibody testing, culture, DNA testing, and histopatholo

112 had been characterized by direct fluorescent antibody test (DFA) and DNA sequencing analysis were tes

113 cytospin-enhanced direct immunofluorescence antibody testing (DFA) and real-time reverse transcripta

114 e performance of culture, direct fluorescent-antibody testing (DFA), and an in-house-developed PCR te

115 citation), evaluated hepatitis C virus (HCV) antibody testing, diagnosis, and costs for each of the i

116 Roche total antibody) and one spike protein antibody test (DiaSorin IgG) were included.

117 consecutively submitted for West Nile virus antibody testing during 2 days of the 2003 West Nile vir

118 ed PCR-based and enzyme-linked immunosorbent antibody test (ELISA) protocols.

119 In general, however, antibody tests, especially DPG-IgA, are of limited value

120 the sensitivity of the standard fluorescent-antibody test (FAT) for rabies antigen and that of hnRT-

121 d for CDV antigen using a direct fluorescent antibody test (FAT).

122 al diagnosis of dermatitis herpetiformis and antibody test findings against aquaporin-4 were positive

123 Screening with the HCV antibody test followed by the nucleic acid test for conf

124 rgy (LAA) by questionnaires and specific-IgE antibody test for 555 rodents and/or rabbit handlers fro

125 d negative results by the direct fluorescent antibody test for respiratory syncytial virus, influenza

126 fever and a positive rapid immunoglobulin M antibody test for typhoid (TUBEX TF); a confirmed case r

127 A rapid HIV-1 antibody test for whole blood was used.

128 Natalizumab, the first anti-integrin antibody tested for treatment of IBD, blocks the alpha4

129 Given that antibody testing for HEV infection is not routinely obta

130 Current antibody testing for human granulocytic ehrlichiosis rel

131 atients with acute viral hepatitis underwent antibody testing for other causes of liver disease and s

132 ere tested by culture and direct fluorescent antibody testing for respiratory syncytial virus (RSV),

133 New antibody tests for antiphospholipid antibody syndrome ar

134 Antibody tests for detecting past infection with severe

135 eds pertaining to the use of anti-SARS-CoV-2 antibody tests for diagnosis, public health surveillance

136 Antibody tests for dpgli yielded superior results compar

137 Antibody tests for identification of current and past in

138 elae, and the potential future importance of antibody tests for vaccine selection and medical screeni

139 Routine antinuclear antibody testing, for example, is not recommended withou

140 ood samples were available for anti-JC virus antibody testing from 5896 patients with multiple sclero

141 ndii infection (a positive anti-T gondii IgM antibody test) from Erechim, Rio Grande do Sul state, Br

142 siblings who did not undergo postvaccination antibody tests (group 2) were studied.

143 assay antigen detection method, and a rapid antibody test had 89 to 100% sensitivity and 89 to 95% s

144 an two-thirds of persons with a positive HCV antibody test had a follow-up RNA test.

145 The anti-rTC antibody test had a sensitivity of 0.50 and a specificit

146 Routine antinuclear antibody testing has a low positive predictive value for

147 Direct fluorescent-antibody testing has a specificity of 99.6% but a sensit

148 Anti-GQ1b antibody testing has allowed clinicians to develop a gre

149 However, as availability of antibody testing has increased, the range of associated

150 canis antigens by indirect immunofluorescent antibody testing have been attributed to infection with

151 Since herpes simplex virus type 2 (HSV-2) antibody tests have become commercially available, an in

152 ning studies that use sensitive and specific antibody tests have revealed the disease to be common, o

153 Current HHV-8 antibody tests have uncertain accuracy in asymptomatic H

154 Among 2535 patients seronegative at first antibody test, HCV incidence was 2.25/100 person-years o

155 Accordingly, the antibodies tested here stained cytoplasmic TRAP brightly

156 d the diagnostic performance of standard HIV antibody tests (i.e., enzyme immunoassay and Western blo

157 Discordant rapid antibody tests identified 7 of 21 (33.3% sensitivity), s

158 ene (16S) PCR and indirect immunofluorescent antibody test (IFA) were retrospectively tested with the

159 enotyping by flow cytometry along with serum antibody testing in 18 kidney transplant recipients with

160 y paediatric neurology centres to Oxford for antibody testing in 2007-2010.

161 ce of H. pylori was determined by biopsy and antibody testing in 84 patients.

162 the positive predictive value of antinuclear antibody testing in diagnosing SLE in a patient with uve

163 bodies of different isotypes, and the use of antibody testing in identification of acutely ill patien

164 limitations, and explores the utility of HLA antibody testing in identifying and managing important p

165 elf-administered questionnaires and oral HIV antibody testing in MSM recruited in gay social venues i

166 determine the sensitivity and specificity of antibody testing in paired serum and CSF samples.

167 sensitivity and specificity of serum and CSF antibody testing in patients with anti-NMDA receptor enc

168 o establish the value of routine antinuclear antibody testing in patients with uveitis.

169 (b) the interpretation of pretransplantation antibody testing in the context of various clinical sett

170 enge that was resolved through rapid typhoid antibody testing in the field and subsequent blood cultu

171 and islet cells), and (c) the application of antibody testing in the posttransplantation setting.

172 independent assays improved the accuracy of antibody tests in low-seroprevalence communities and rev

173 is study aimed to compare the performance of antibody tests in predicting small-intestinal mucosal st

174 A combination of three or four antibody tests including IgA anti-tissue transglutaminas

175 ghly correlated with two commercial COVID-19 antibody tests, including an enzyme linked immunosorbent

176 hology, molecular technologies and sensitive antibody testing into one enhanced diagnostic system.

177 Accordingly, the JCV serological antibody test is of paramount importance in determining

178 nucleic acid test (NAT) for HCV RNA when the antibody test is positive, are compared.

179 interference when the indirect fluorescence antibody test is used to detect fluorescence of morulae

180 Limited HHV-8 antibody testing is available through some US reference

181 Antibody testing is especially important in understandin

182 Antigliadin antibody testing is essential at first presentation of p

183 The sensitivity of NMDA receptor antibody testing is higher in CSF than in serum.

184 Antibody testing is often useful for the identification

185 of brain natriuretic peptide, and leukocyte antibody testing is the best strategy currently availabl

186 sensitivity of acetylcholine receptor (AChR) antibody testing is thought to be lower in ocular myasth

187 ence (t-CyCIF) as an imaging platform, these antibody-testing methods are broadly applicable.

188 gal-specific laboratory test: histoplasmosis antibody test (n = 349 [18%]), Histoplasma antigen test

189 One-time antibody test of 1945-1965 birth cohort.

190 anced surveillance of measles, including IgM antibody testing of oral fluid from clinically diagnosed

191 Indirect immunofluorescent antibody testing of serum from 57 blood donors implicate

192 Immunoglobulin M antibody testing of serum specimens and cerebrospinal fl

193 From 2003-2010, 5860 persons had a positive antibody test, of whom 3570 (60.9%) had a follow-up RNA

194 The indirect fluorescence antinuclear antibody test on Hep-2 cells demonstrated antinuclear ti

195 blic clinics employed the OraQuick HCV rapid antibody test on site, and all results were verified by

196 for rhesus monkeys on the basis of sensitive antibody tests only.

197 Of the anti-syntaxin antibodies tested, only anti-syntaxin 2 antibody inhibit

198 showed that: (i) of the purified or elicited antibodies tested, only antibodies against the N-termina

199 that tested positive in a direct fluorescent-antibody test or in a confirmatory PCR test for an alter

200 or cell lysates was revealed by fluorescent antibody testing or enzyme-linked immunosorbent assay, r

201 criptase polymerase chain reaction (RT-PCR), antibody testing, or exposure to persons with Covid-19 i

202 ting with the OraQuick ADVANCE Rapid HIV-1/2 Antibody Test (OraSure Technologies, Bethlehem, Pennsylv

203 In conclusion, two nucleocapsid antibody tests outperformed a spike protein antibody tes

204 s were more sensitive than the spike protein antibody test overall (70% and 70% versus 57%; P <= 0.00

205 Patients who had only direct fluorescent antibody testing performed or concurrent viral infection

206 t results who also had T. gondii IgA and IgM antibody tests performed.

207 Unlike several Epac-specific antibodies tested, Phi-O-Me-cAMP exhibited dramatically

208 2 infection in the mask wearer at 1 month by antibody testing, polymerase chain reaction (PCR), or ho

209 ot fully understood, but it is believed that antibodies testing positive in the serotonin release ass

210 dies to intact platelets and found that most antibodies testing positive in the SRA, but none of thos

211 Advances in the efficacy of serological antibody testing potentiate the possibility of future ac

212 The panel reactive antibody test (PRA) is an established method for assessi

213 ics switched from a direct immunofluorescent antibody testing procedure to an enzyme immunoassay with

214 Combining antigen and EIA antibody testing provides an optimal method for diagnosi

215 Given uncertainty about the antibody tests (quality, accuracy level, positive predic

216 All patients underwent HLA-antibody testing quarterly pretransplant and at regular

217 g to determine whether the results of an IgM antibody test reflect the likelihood of a recently acqui

218 While molecular-based and antibody tests remain the reference standard method for

219 o submitted convalescent serum specimens for antibody testing, respiratory tract virus infections wer

220 Women were less likely to have a positive antibody test result (OR, 0.36; 95% CI, 0.19-0.68; P = .

221 ection, one-third of whom had a negative HCV antibody test result at the time of the HCV RNA positivi

222 ts and detectable HCV RNA, or a positive HCV antibody test result if HCV RNA measurements were not av

223 ts and detectable HCV RNA, or a positive HCV antibody test result if HCV RNA measurements were not av

224 ion assay or indirect fluorescent treponemal antibody test result), compared with 3 (1%) of 233 uninf

225 ere significantly associated with a positive antibody test result.

226 Antinuclear antibodies test results were negative.

227 e pregnant women with positive T. gondii IgG antibody test results who also had T. gondii IgA and IgM

228 ormed on subjects regardless of symptoms, or antibody test results.

229 e the probability of seropositivity prior to antibody test results.

230 were significantly associated with positive antibody test results.

231 Among the 223 participants, AChR antibody testing results were positive in 158 participan

232 -reduced blood products and standardized HLA antibody testing, roughly one-third developed new Class

233 -reduced blood products and standardized HLA antibody testing, roughly one-third developed new class

234 ecificity remain undetermined, cerebrospinal antibody testing should also be performed.

235 ed to inform individual decision making, and antibody testing should remain a tool of public health a

236 Antigen/antibody tests should be preferred to avoid missing case

237 All of eight anti-tau antibodies tested showed dephosphorylation at 0 h and hy

238 d PHA-L--labeled afferents, 3 of 5 anti-TrkB antibodies tested showed significant colocalization with

239 sitive staining for all phospho-tau-specific antibodies tested, similar to the pattern seen in human

240 observations, CD4-Ig, but none of the CD4bs antibodies tested, substantially increased HIV-1 infecti

241 Rapid human immunodeficiency virus (HIV) antibody tests support the effort to expand access to HI

242 computerized algorithm, termed the Kentucky Antibody Testing System (KATS), that predicts class I HL

243 15 were randomly selected for infection and antibody testing: TF and TT were assessed, conjunctival

244 ntly higher positive rate for anti-mouse IgE antibody test than the other (38.1% vs 8.8%, p<0.01) .

245 We demonstrate a higher sensitivity of AChR antibody testing than previously reported in the largest

246 eview focuses on the individual relevance of antibody tests: their accuracy in detecting prior infect

247 ntains epitopes for all monoclonal and human antibodies tested to date.

248 Glycoprotein G is currently the target of an antibody test to differentiate HSV-1 from HSV-2; however

249 of the average time from the first positive antibody test to the diagnosis are underestimates of the

250 atients referred on clinical grounds for RNP antibody testing to a reference laboratory between 1989

251 Physicians must perform HIV antibody testing to determine which persons are already

252 ning strategies now involve ANA and anti-DNA antibody testing to identify patients with so-called 'ac

253 Because HSV glycoproteins are the focus of antibody tests to detect and differentiate between infec

254 immunodeficiency virus (HIV) to standard HIV antibody tests to detect persons with acute HIV infectio

255 was to compare celiac disease (CD)- specific antibody tests to determine if they could replace jejuna

256 received both HBsAg and hepatitis B surface antibody tests to determine prior exposure and susceptib

257 ich may account for the failure of sensitive antibody tests to distinguish HSV-1 from HSV-2 in some A

258 l HIVST kits (OraQuick ADVANCE Rapid HIV-1/2 Antibody Test) to adult (>/=16 y old) residents (n = 16,

259 The symposium focused on antibody testing, transplantation pathology, molecular d

260 However, antibody testing using cells expressing voltage-gated po

261 This paper describes the dynamics of BVDV antibody test values (measured as percentage positivity

262 Assessments included rapid HIV antibody testing, VL, and CD4+ T-cell count via fingerpr

263 No elimination of antiviral antibodies tested was seen.

264 en into account, the sensitivity of standard antibody testing was 0.962 (95 percent confidence interv

265 tive predictive value of routine antinuclear antibody testing was 2.9% (95% CI, 2.65%-3.19%).

266 Non-HLA antibody testing was included in the posttransplant eval

267 cal serotype-specific immunoglobulin G (IgG) antibody testing was offered as a clinical service to al

268 Ehrlichia antibody testing was performed by using an indirect immu

269 Anti-HCV antibody testing was performed for 4582, or 90%, of all

270 HAV antibody testing was performed in 640 subjects (53.6%),

271 boratory, autoantibody, and antiphospholipid antibody testing was performed in the hospitals' clinica

272 HCV antibody testing was performed on excess samples.

273 Anti-Porphyromonas gingivalis antibody testing was performed to assess prior exposure

274 For antibody testing, we used an Ebola virus glycoprotein Ig

275 Four out of the 12 monoclonal antibodies tested were also unable to neutralize the vir

276 Several of the antibodies tested were found to bind to regions already

277 ewhat surprising, the majority of commercial antibodies tested were unable to specifically recognize

278 IgA endomysial antibodies tests were associated with high specificity.

279 Specimens for solid-phase HLA antibody testing were available in 199 patients.

280 xposures and blood samples for H5N1-specific antibody testing were collected.

281 tion studies, and indirect immunofluorescent antibody testing were used to confirm the presence of Ba

282 Over a one-month period, HCV antibody tests were conducted in 905 individuals with a

283 ed persistently seronegative (HIPS) on HIV-1 antibody tests were examined through AIDS case surveilla

284 The two nucleocapsid antibody tests were more sensitive than the spike protei

285 Of the 8155 at-risk individuals whose antibody tests were negative, 5 were HIV RNA positive.

286 HCV antibody tests were performed by the enzyme-linked immun

287 cts were interviewed and examined, and serum antibody tests were performed, along with blood cultures

288 es that yielded negative results on standard antibody tests were tested again with the use of nucleic

289 was the most potent antagonistic anti-IGF-IR antibody tested when compared with several commercially

290 s (HCV) RNA testing offers an advantage over antibody testing (which only indicates previous exposure

291 diagnostic limitations of direct fluorescent-antibody testing, which missed one-third of infected ind

292 IA offers increased sensitivity over current antibody tests while also allowing separate detection of

293 ization and normalization of solid phase HLA antibody tests will enable comparison of data across lab

294 as resistant to neutralization by all of the antibodies tested with the exception of the 2G12 antibod

295 e tested for influenza by direct fluorescent-antibody testing with PCR confirmation.

296 nimals did not react in indirect fluorescent-antibody tests with Babesia microti antigen, however, su

297 currently a number of commercial SARS-CoV-2 antibody tests with emergency use authorization (EUA) fr

298 V antigen, the development of diagnostic HAV antibody tests with recombinant HAV antigen appears warr

299 new sample because they did not have an HLA antibody test within the preceding 3 months or because t

300 ow point-of-care test, the WONDFO SARS-CoV-2 Antibody Test (Wondfo Biotech, Guangzhou, China), using